Lincoln Pharmaceuticals Ltd
Lincoln Pharmaceuticals Q3 FY24 earnings call: Revenue & Margins
Q3 FY24 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹146Cr
- Net profit
- ₹28Cr
- Margin
- 20%
Guidance rank: #54 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on Lincoln Pharmaceuticals Ltd's Q3 FY24 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
The presentation reports the following figures for the quarter: - EBITDA: ₹1,150 crore, showing a year-on-year increase of 34%.
From Lincoln Pharmaceuticals Ltd's Q3 FY24 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
See what Lincoln Pharmaceuticals Ltd said on revenue & sales performance — free account, 30 seconds.
Profitability & Margins
See what Lincoln Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
See what Lincoln Pharmaceuticals Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Lincoln Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Lincoln Pharmaceuticals Ltd said on order book & pipeline — free account, 30 seconds.
Lincoln Pharmaceuticals Ltd — Quarterly revenue & net profit
Lincoln Pharmaceuticals Ltd Q3 FY24 results — key figures
| ₹ Cr | Q3 FY24 | Q2 FY24 | QoQ |
|---|---|---|---|
| Revenue | 146 | 156 | -6.4% |
| Operating profit (EBITDA) | 30 | 31 | -3.2% |
| Operating margin | 20% | 20% | 0 pp |
| Profit before tax | 38 | 37 | +2.7% |
| Net profit (PAT) | 28 | 28 | 0% |
| EPS (₹) | 14.00 | 13.80 | +1.4% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹191 Cr, net profit ₹20 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Lincoln Pharmaceuticals's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q2 FY25 earnings call analysis →
- Q4 FY24 earnings call →
Earlier calls (1)
Others in Pharmaceuticals & Biotechnology this season
- Wockhardt (Q3 FY24)
Net Sales Revenues for 9M FY24: INR 2,129 Cr. Key concall takeaways from Wockhardt Ltd's Q3 FY24 earnings call — and how it ranks against sector peers.
- NGL Fine Chem (Q3 FY24)
Q3FY24 Revenue from Operations: ₹87.95 crore, up 22.27% year-on-year (YoY) from Q3FY23 ₹71.93 crore (Page 8). Key concall takeaways from NGL Fine Chem Ltd's Q3…
- Anuh Pharma (Q3 FY24)
172.10 Cr, a 15% increase quarter-on-quarter and 31% year-on-year over 9M FY23. Key concall takeaways from Anuh Pharma Ltd's Q3 FY24 earnings call — and how it…
- Bharat Parenterals (Q3 FY24)
Revenue from operations: ₹58.8 crore (down 0.4% YoY) . Key concall takeaways from Bharat Parenterals Ltd's Q3 FY24 earnings call — and how it ranks against…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Lincoln Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Lincoln Pharmaceuticals Ltd Q3 FY24 results?
The presentation reports the following figures for the quarter: - EBITDA: ₹1,150 crore, showing a year-on-year increase of 34%.
What is Lincoln Pharmaceuticals Ltd share price analysis?
Lincoln Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 12.6 with a market cap of ₹1,212 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Lincoln Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.